Joanna S. Yi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Joanna S. Yi has a total of 237 co-authors. Here are the top co-authors by number of shared publications:
Michael E. Scheurer
Division of Pediatric Hematology/Oncology Texas Children's Hospital, Baylor College of Medicine Houston Texas USA
3 shared publications- Amber Gibson
Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
2 shared publications - Branko Cuglievan
Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, USA
2 shared publications Connor G Burke
2 shared publications- Courtney Denton Dinardo
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA
2 shared publications Dahlya Kamarudin
2 shared publications
Latest Publications
- Open Access
- 26 September 2026
- Published by Elsevier in Blood Neoplasia
EZH2-driven immune evasion at disease presentation defines high-risk t(16;21) FUS::ERG pediatric AML
- 26 September 2026
- Published by Elsevier in Blood Neoplasia
Open AccessEZH2-driven immune evasion at disease presentation defines high-risk t(16;21) FUS::ERG pediatric AML
- 25 September 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (10)
CAMKV kinase drives neuroblastoma growth and acts as a novel therapeutic target
High-risk (HR) neuroblastoma (NB) remains a leading cause of pediatric cancer mortality, frequently driven by MYCN amplification or MYC overexpression. Despite their central role, direct pharmacological targeting of these transcription factors remains clinically challenging. Here, we identify CaM kinase–like vesicle-associated protein (CAMKV) as a MYCN/MYC-regulated effector of NB pathogenesis. Although previously classified as a nonfunctional pseudokinase, we demonstrate that CAMKV possesses intrinsic kinase activity that is essential for tumor growth. Analysis of patient datasets and primary tumors shows that elevated CAMKV expression correlates with advanced disease stage and poor overall survival. Through integrated transcriptomics, ChIP-seq, and phosphoproteomics, we establish CAMKV as a central signaling hub that coordinates metabolic and proliferative pathways. Both genetic depletion and small-molecule inhibition of CAMKV significantly impair NB cell proliferation in vitro and suppress tumor growth in vivo. Collectively, our findings establish CAMKV as a unifying therapeutic vulnerability and highlight this functional kinase as a promising target for translational development in HR NB.
- 25 September 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (10)
CAMKV kinase drives neuroblastoma growth and acts as a novel therapeutic target
High-risk (HR) neuroblastoma (NB) remains a leading cause of pediatric cancer mortality, frequently driven by MYCN amplification or MYC overexpression. Despite their central role, direct pharmacological targeting of these transcription factors remains clinically challenging. Here, we identify CaM kinase–like vesicle-associated protein (CAMKV) as a MYCN/MYC-regulated effector of NB pathogenesis. Although previously classified as a nonfunctional pseudokinase, we demonstrate that CAMKV possesses intrinsic kinase activity that is essential for tumor growth. Analysis of patient datasets and primary tumors shows that elevated CAMKV expression correlates with advanced disease stage and poor overall survival. Through integrated transcriptomics, ChIP-seq, and phosphoproteomics, we establish CAMKV as a central signaling hub that coordinates metabolic and proliferative pathways. Both genetic depletion and small-molecule inhibition of CAMKV significantly impair NB cell proliferation in vitro and suppress tumor growth in vivo. Collectively, our findings establish CAMKV as a unifying therapeutic vulnerability and highlight this functional kinase as a promising target for translational development in HR NB.
- 29 July 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (9)
Recurrent Hypoglycemia Following Asparaginase Therapy for Lymphoid Malignancies in Childhood: The Texas Children's Hospital Experience
Background: Hypoglycemia is a rarely reported complication of asparaginase (ASP) therapy in children with acute lymphoblastic leukemia/lymphoma (ALL/LLy). We sought to identify risk factors and outcomes among patients with ASP‐induced hypoglycemia (AIH) at our institution. Methods: Retrospective cohort study using electronic medical records to identify all patients who received ASP and had diagnosis of hypoglycemia between June 1, 2017 and June 30, 2022. Demographic and clinically relevant data were collected. Results: A total of 672 patients received ASP, with 8% having AIH—defined by a measured low blood glucose level within 14 days of ASP administration and other causes of hypoglycemia excluded. Median age at ALL/LLy diagnosis was 4.4 years (inter‐quartile range [IQR]: 2.5–7.7) that was younger than a comparison cohort of patients without AIH (median 6.7 years, p value 0.01). Median BMI z ‐score was 0.50 (IQR: −0.46 to 0.95). Initial hypoglycemia event was during Induction therapy in 71%, with a median of 11 days (IQR: 6–15) from ASP to hypoglycemia diagnosis. Median duration of the hypoglycemia episode was 11 days (IQR: 7–19). Recurrent hypoglycemia with subsequent ASP doses occurred in 84% of patients, with a median duration of 14 days (IQR: 8–21). Overall survival of the AIH cohort was 80% (85% if limited to patients with newly diagnosed ALL/LLy), with 3‐year median follow‐up. In univariate analysis, hypoglycemia severity was not associated with age, sex, ethnicity, or weight. Conclusion: AIH is relatively common with no clear risk factors besides younger age. It can recur and become more severe with longer duration. AIH screening and management should be implemented.
- 29 July 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (9)
Recurrent Hypoglycemia Following Asparaginase Therapy for Lymphoid Malignancies in Childhood: The Texas Children's Hospital Experience
Background: Hypoglycemia is a rarely reported complication of asparaginase (ASP) therapy in children with acute lymphoblastic leukemia/lymphoma (ALL/LLy). We sought to identify risk factors and outcomes among patients with ASP‐induced hypoglycemia (AIH) at our institution. Methods: Retrospective cohort study using electronic medical records to identify all patients who received ASP and had diagnosis of hypoglycemia between June 1, 2017 and June 30, 2022. Demographic and clinically relevant data were collected. Results: A total of 672 patients received ASP, with 8% having AIH—defined by a measured low blood glucose level within 14 days of ASP administration and other causes of hypoglycemia excluded. Median age at ALL/LLy diagnosis was 4.4 years (inter‐quartile range [IQR]: 2.5–7.7) that was younger than a comparison cohort of patients without AIH (median 6.7 years, p value 0.01). Median BMI z ‐score was 0.50 (IQR: −0.46 to 0.95). Initial hypoglycemia event was during Induction therapy in 71%, with a median of 11 days (IQR: 6–15) from ASP to hypoglycemia diagnosis. Median duration of the hypoglycemia episode was 11 days (IQR: 7–19). Recurrent hypoglycemia with subsequent ASP doses occurred in 84% of patients, with a median duration of 14 days (IQR: 8–21). Overall survival of the AIH cohort was 80% (85% if limited to patients with newly diagnosed ALL/LLy), with 3‐year median follow‐up. In univariate analysis, hypoglycemia severity was not associated with age, sex, ethnicity, or weight. Conclusion: AIH is relatively common with no clear risk factors besides younger age. It can recur and become more severe with longer duration. AIH screening and management should be implemented.
- 20 November 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (21) , 2608-2611
FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML
FLAG-IDA (fludarabine, cytarabine, granulocyte colony-stimulating factor, idarubicin) with venetoclax shows promise as frontline pediatric acute myeloid leukemia therapy. In 12 patients treated at MD Anderson, most achieved remission with good early survival outcomes, and many proceeded to transplant. Common toxicities included cytopenias, comparable to previous regimens.
- 20 November 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (21) , 2608-2611
FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML
FLAG-IDA (fludarabine, cytarabine, granulocyte colony-stimulating factor, idarubicin) with venetoclax shows promise as frontline pediatric acute myeloid leukemia therapy. In 12 patients treated at MD Anderson, most achieved remission with good early survival outcomes, and many proceeded to transplant. Common toxicities included cytopenias, comparable to previous regimens.
- Open Access
- 16 November 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (22) , 5802-5810
An analysis of diagnostic metabolomic profiles associated with hepatotoxicity during childhood ALL induction therapy
Hepatotoxicity is a well-documented complication of induction chemotherapy for acute lymphoblastic leukemia (ALL), but our understanding of its biological mechanisms is limited. We identified 314 patients with ALL (aged 1-19 years) treated at Texas Children’s Hospital (2008-2019) with diagnostic bone marrow plasma available for metabolomic profiling: 234 for discovery and 80 for replication. Hepatotoxicity during induction was defined as follows: (1) transaminitis: grade ≥3 aspartate aminotransferase or alanine aminotransferase or (2) conjugated hyperbilirubinemia: conjugated bilirubin (c.bili) >3 mg/dL. Untargeted profiling detected 519 metabolites. Adjusted odds ratios (aORs) for each metabolite were calculated with logistic regression, accounting for sex, age, body mass index, race/ethnicity, and treatment intensity. The population was 56% Latino, 57% male, 92% B-ALL, 25% overweight/obese, and 57% National Cancer Institute standard-risk at a median age of 5 years. Transaminitis was observed in 34% of the discovery and 24% of the replication cohort. Seven instances of c.bili >3 mg/dL were observed in the discovery cohort, with none in the replication cohort. Furthermore, 12 metabolites were associated with transaminitis (P < .05) in the discovery cohort, including 2 that replicated (P < .05): 1,2-dipalmitoyl-glycerophosphocholine (GPC) (aOR combined = 1.88 [95% confidence interval [CI], 1.26-2.79], P = .002) and 1-(1-enyl-palmitoyl)-2-palmitoleoyl-GPC (aOR combined = 1.56 [95% CI: 1.17-2.09], P = .003). In the discovery cohort, 34 metabolites were associated with c.bili >3 mg/dL, including the top association of 1,2-dipalmitoyl-GPC (aOR = 5.76 [95% CI: 2.20-23.16], P = .002). We observed and replicated associations between phosphatidylcholine metabolites at ALL diagnosis and hepatotoxicity during induction therapy, suggesting a potential role for lipid dysregulation in the development of hepatotoxicity.
- 16 November 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (22) , 5802-5810
Open AccessAn analysis of diagnostic metabolomic profiles associated with hepatotoxicity during childhood ALL induction therapy
Hepatotoxicity is a well-documented complication of induction chemotherapy for acute lymphoblastic leukemia (ALL), but our understanding of its biological mechanisms is limited. We identified 314 patients with ALL (aged 1-19 years) treated at Texas Children’s Hospital (2008-2019) with diagnostic bone marrow plasma available for metabolomic profiling: 234 for discovery and 80 for replication. Hepatotoxicity during induction was defined as follows: (1) transaminitis: grade ≥3 aspartate aminotransferase or alanine aminotransferase or (2) conjugated hyperbilirubinemia: conjugated bilirubin (c.bili) >3 mg/dL. Untargeted profiling detected 519 metabolites. Adjusted odds ratios (aORs) for each metabolite were calculated with logistic regression, accounting for sex, age, body mass index, race/ethnicity, and treatment intensity. The population was 56% Latino, 57% male, 92% B-ALL, 25% overweight/obese, and 57% National Cancer Institute standard-risk at a median age of 5 years. Transaminitis was observed in 34% of the discovery and 24% of the replication cohort. Seven instances of c.bili >3 mg/dL were observed in the discovery cohort, with none in the replication cohort. Furthermore, 12 metabolites were associated with transaminitis (P < .05) in the discovery cohort, including 2 that replicated (P < .05): 1,2-dipalmitoyl-glycerophosphocholine (GPC) (aOR combined = 1.88 [95% confidence interval [CI], 1.26-2.79], P = .002) and 1-(1-enyl-palmitoyl)-2-palmitoleoyl-GPC (aOR combined = 1.56 [95% CI: 1.17-2.09], P = .003). In the discovery cohort, 34 metabolites were associated with c.bili >3 mg/dL, including the top association of 1,2-dipalmitoyl-GPC (aOR = 5.76 [95% CI: 2.20-23.16], P = .002). We observed and replicated associations between phosphatidylcholine metabolites at ALL diagnosis and hepatotoxicity during induction therapy, suggesting a potential role for lipid dysregulation in the development of hepatotoxicity.
- 1 October 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500225
Sustained Response to Pan-BRAF Inhibitor Plixorafenib (FORE8394, PLX8394) in a Young Adult With Neurodegenerative Langerhans Cell Histiocytosis
- 1 October 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500225
Sustained Response to Pan-BRAF Inhibitor Plixorafenib (FORE8394, PLX8394) in a Young Adult With Neurodegenerative Langerhans Cell Histiocytosis
- 18 March 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (6) , e31657
Acute Leukemia in the Crosshairs: First‐in‐Class Menin Inhibitor Approval for Adults and Children
- 18 March 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (6) , e31657
Acute Leukemia in the Crosshairs: First‐in‐Class Menin Inhibitor Approval for Adults and Children
- Open Access
- 1 October 2024
- Published by Wiley
Recurrent Hypoglycemia Following Asparaginase Therapy for Lymphoid Malignancies in Childhood: The Texas Children’s Hospital Experience
Background : Hypoglycemia is a rarely reported complication of Asparaginase (ASP) therapy in children with lymphoblastic leukemia/lymphoma (ALL/LLy). We sought to identify risk factors and outcomes among patients with ASP-induced hypoglycemia (AIH) at our institution. Methods : Retrospective cohort study using electronic medical records to identify all patients who received ASP and had diagnosis of hypoglycemia between 6/1/2017-6/30/2022. Demographic and clinically relevant data were collected. Results : A total of 672 patients received ASP, with 8% having AIH–defined by a measured low blood glucose level within 14 days of ASP administration and other causes of hypoglycemia excluded. Median age at ALL/LLy diagnosis was 4.4 years (Interquartile range [IQR]: 2.5 – 7.7) which was younger than patients without AIH (median 6.9 years, p-value 0.005), and median BMI z-score 0.50 (IQR: -0.46 – 0.95). Initial hypoglycemia event was during Induction therapy in 71%, with median time from ASP to hypoglycemia diagnosis of 11 days (IQR: 6-15). Median duration of the hypoglycemia episode was 11 days (IQR: 7-19). Recurrent hypoglycemia with subsequent ASP doses occurred in 84% of patients, with a median duration 14 days (IQR: 8-21). Overall survival of the AIH cohort was 80% (85% if limited to patients with newly diagnosed ALL/LLy), with 3 years’ median follow up. In univariate analysis, hypoglycemia severity was not associated with age, sex, ethnicity, or weight. Conclusion : AIH is relatively common with no clear risk factors besides younger age. It can recur and become more severe with longer duration. AIH screening and management should be implemented.
- 1 October 2024
- Published by Wiley
Open AccessRecurrent Hypoglycemia Following Asparaginase Therapy for Lymphoid Malignancies in Childhood: The Texas Children’s Hospital Experience
Background : Hypoglycemia is a rarely reported complication of Asparaginase (ASP) therapy in children with lymphoblastic leukemia/lymphoma (ALL/LLy). We sought to identify risk factors and outcomes among patients with ASP-induced hypoglycemia (AIH) at our institution. Methods : Retrospective cohort study using electronic medical records to identify all patients who received ASP and had diagnosis of hypoglycemia between 6/1/2017-6/30/2022. Demographic and clinically relevant data were collected. Results : A total of 672 patients received ASP, with 8% having AIH–defined by a measured low blood glucose level within 14 days of ASP administration and other causes of hypoglycemia excluded. Median age at ALL/LLy diagnosis was 4.4 years (Interquartile range [IQR]: 2.5 – 7.7) which was younger than patients without AIH (median 6.9 years, p-value 0.005), and median BMI z-score 0.50 (IQR: -0.46 – 0.95). Initial hypoglycemia event was during Induction therapy in 71%, with median time from ASP to hypoglycemia diagnosis of 11 days (IQR: 6-15). Median duration of the hypoglycemia episode was 11 days (IQR: 7-19). Recurrent hypoglycemia with subsequent ASP doses occurred in 84% of patients, with a median duration 14 days (IQR: 8-21). Overall survival of the AIH cohort was 80% (85% if limited to patients with newly diagnosed ALL/LLy), with 3 years’ median follow up. In univariate analysis, hypoglycemia severity was not associated with age, sex, ethnicity, or weight. Conclusion : AIH is relatively common with no clear risk factors besides younger age. It can recur and become more severe with longer duration. AIH screening and management should be implemented.
- Open Access
EZH2-driven immune evasion at disease presentation defines a targetable high-risk subset of acute leukemia exemplified by t(16;21) FUS::ERG AML
The past 25 years of clinical trials have produced few improvements in pediatric AML (pAML) outcomes. This is acutely evident in patients with t(16;21)(p11;q22), yielding FUS::ERG . Patients with FUS::ERG -positive AML relapse quickly and do not respond to transplantation. Major histocompatibility complex (MHC) class I & II receptors and costimulatory molecules are absent at diagnosis in FUS::ERG- positive AML, mirroring the phenotype and outcomes of post-transplant relapse. We show that this is driven by overexpression of EZH2, in vitro and in multiple clinical cohorts. While FUS::ERG AML is the most extreme example, this phenotype is shared by lethal CBFA2T3::GLIS2- driven AML, and patients with RUNX1::RUNX1T1 have significantly worse outcomes when EZH2 overexpression co-occurs. The FDA-approved EZH2 inhibitor tazemetostat reverses this phenotype, re-establishes MHC presentation, and elicits immune effector cell-mediated elimination. EZH2 inhibitors may provide the first targeted therapeutic frontline option for AML patients with FUS::ERG , with the potential for broader frontline immunostimulatory benefits. STATEMENT OF SIGNIFICANCE: Here we show an immune-evasive phenotype, present at diagnosis and characterized by elevated EZH2 levels and loss of MHC class I and II, defines a high-risk subtype of acute leukemia. Treatment with the EZH2 inhibitor tazemetostat and IFN-γ reverses this phenotype and results in immune cell engagement and blast elimination.
Open AccessEZH2-driven immune evasion at disease presentation defines a targetable high-risk subset of acute leukemia exemplified by t(16;21) FUS::ERG AML
The past 25 years of clinical trials have produced few improvements in pediatric AML (pAML) outcomes. This is acutely evident in patients with t(16;21)(p11;q22), yielding FUS::ERG . Patients with FUS::ERG -positive AML relapse quickly and do not respond to transplantation. Major histocompatibility complex (MHC) class I & II receptors and costimulatory molecules are absent at diagnosis in FUS::ERG- positive AML, mirroring the phenotype and outcomes of post-transplant relapse. We show that this is driven by overexpression of EZH2, in vitro and in multiple clinical cohorts. While FUS::ERG AML is the most extreme example, this phenotype is shared by lethal CBFA2T3::GLIS2- driven AML, and patients with RUNX1::RUNX1T1 have significantly worse outcomes when EZH2 overexpression co-occurs. The FDA-approved EZH2 inhibitor tazemetostat reverses this phenotype, re-establishes MHC presentation, and elicits immune effector cell-mediated elimination. EZH2 inhibitors may provide the first targeted therapeutic frontline option for AML patients with FUS::ERG , with the potential for broader frontline immunostimulatory benefits. STATEMENT OF SIGNIFICANCE: Here we show an immune-evasive phenotype, present at diagnosis and characterized by elevated EZH2 levels and loss of MHC class I and II, defines a high-risk subtype of acute leukemia. Treatment with the EZH2 inhibitor tazemetostat and IFN-γ reverses this phenotype and results in immune cell engagement and blast elimination.
- Open Access
KMT2A oncoproteins induce epigenetic resistance to targeted therapies
Chromosomal translocations involving the Lysine-Methyl-Transferase-2A ( KMT2A ) locus generate potent oncogenic fusion proteins (oncoproteins) that disrupt regulation of developmental gene expression. By profiling the oncoprotein-target sites of 36 broadly representative KMT2A -rearranged leukemia samples, including three samples that underwent a lymphoid-to-myeloid lineage-switching event in response to therapy, we find the genomic enrichment of the oncoprotein is highly variable between samples and subject to dynamic regulation. At high levels of expression, the oncoproteins preferentially activate either an acute lymphoblastic leukemia (ALL) program, enriched for pro-B-cell genes, or an acute myeloid leukemia (AML) program, enriched for hematopoietic-stem-cell genes. The fusion-partner-specific-binding patterns over these gene sets are highly correlated with the prevalence of each mutation in ALL versus AML. In lineage-switching samples the oncoprotein levels are reduced and the oncoproteins preferentially activate granulocyte-monocyte progenitor (GMP) genes. In a sample that lineage switched during treatment with the menin inhibitor revumenib, the oncoprotein and menin are reduced to undetectable levels, but ENL, a transcriptional cofactor of the oncoprotein, persists on numerous oncoprotein-target loci, including genes in the GMP-like lineage-switching program. We propose KMT2A oncoproteins promote lineage-switching events through dynamic chromatin binding and can induce epigenetic lesions, marked by ENL, that support resistance to targeted therapies.
Open AccessKMT2A oncoproteins induce epigenetic resistance to targeted therapies
Chromosomal translocations involving the Lysine-Methyl-Transferase-2A ( KMT2A ) locus generate potent oncogenic fusion proteins (oncoproteins) that disrupt regulation of developmental gene expression. By profiling the oncoprotein-target sites of 36 broadly representative KMT2A -rearranged leukemia samples, including three samples that underwent a lymphoid-to-myeloid lineage-switching event in response to therapy, we find the genomic enrichment of the oncoprotein is highly variable between samples and subject to dynamic regulation. At high levels of expression, the oncoproteins preferentially activate either an acute lymphoblastic leukemia (ALL) program, enriched for pro-B-cell genes, or an acute myeloid leukemia (AML) program, enriched for hematopoietic-stem-cell genes. The fusion-partner-specific-binding patterns over these gene sets are highly correlated with the prevalence of each mutation in ALL versus AML. In lineage-switching samples the oncoprotein levels are reduced and the oncoproteins preferentially activate granulocyte-monocyte progenitor (GMP) genes. In a sample that lineage switched during treatment with the menin inhibitor revumenib, the oncoprotein and menin are reduced to undetectable levels, but ENL, a transcriptional cofactor of the oncoprotein, persists on numerous oncoprotein-target loci, including genes in the GMP-like lineage-switching program. We propose KMT2A oncoproteins promote lineage-switching events through dynamic chromatin binding and can induce epigenetic lesions, marked by ENL, that support resistance to targeted therapies.